Headlines about aTyr Pharma (NASDAQ:LIFE) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. aTyr Pharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.0850007779817 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of research firms recently issued reports on LIFE. ValuEngine downgraded shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Saturday, November 18th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $4.81.
Shares of aTyr Pharma (LIFE) opened at $3.90 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.49 and a current ratio of 9.49. aTyr Pharma has a 52 week low of $2.30 and a 52 week high of $6.50. The stock has a market cap of $116.06, a P/E ratio of -1.92 and a beta of 3.83.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.07. sell-side analysts predict that aTyr Pharma will post -1.93 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/01/14/atyr-pharma-life-receiving-somewhat-positive-press-coverage-study-shows.html.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.